In conclusion, our pan-cancer analytical framework revealed distinct expression patterns of the WFDC family and identified WFDC3 as a promising prognostic biomarker and therapeutic target in PAAD, owing to its dual association with metastatic progression and modulation of the immune microenvironment. Here, WFDC3 is linked to pancreatic adenocarcinoma.